News & Events

Corporate Presentation

Download June 2025 Presentation

Select Highlights

June 2, 2025

Latest Press Releases

June 2, 2025

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi

May 19, 2025

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

May 7, 2025

Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria

February 10, 2025

Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

More Press Releases

Events and Presentations

May 18, 2025

Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammation

View Poster »

May 8, 2025

Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous Urticaria

View Poster »

December 7, 2023

STAT6 Program Highlighted in Sanofi R&D Day

Access Webcast »

News Coverage Highlights

August 7, 2023

BioCentury: Recludix: targeting STATs via their SH2 domains

July 20, 2023

BioWorld: Recludix enters a potential $1.2B deal with Sanofi

July 20, 2023

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

July 20, 2023

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

July 20, 2023

Corporate Presentation

Select Highlights

News: STAT6 DC Nomination

ATS Conference: STAT6 Data

SID Conference: BTK Data

Latest Press Releases

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria

Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Events and Presentations

Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammation

Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous Urticaria

STAT6 Program Highlighted in Sanofi R&D Day

News Coverage Highlights

BioCentury: Recludix: targeting STATs via their SH2 domains

BioWorld: Recludix enters a potential $1.2B deal with Sanofi

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix